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Abstract
Background Previous studies have shown that xanthine oxidase inhibitors (XOI) might improve outcome for patients with
cardiovascular disease. However, more evidence is required.
Methods and results We published a meta-analysis of trials conducted before 2014 examining the effects of XOI on
mortality in patients with cardiovascular disease. At least two further trials (N = 323 patients) have since been published.
Accordingly, we repeated our analysis after a further search for randomized controlled trials of XOI in PubMed/MEDLINE,
EMBASE, and Cochrane Databases. We identiﬁed eight relevant trials with 1031 patients. The average age of the patients
was 61 years and 68% were men (one study did not report gender). There were 57 deaths in these eight trials, 26 in those
assigned to XOI, and 31 in those assigned to the control. The updated meta-analysis could not conﬁrm a reduction in
mortality for patients assigned to XOI compared with placebo (odds ratio 0.84) but 95% conﬁdence intervals were
wide (0.48–1.47).
Conclusions This updated meta-analysis does not suggest that XOI exert a large reduction in mortality but also cannot
exclude the possibility of substantial harm or beneﬁt.
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Introduction
Xanthine oxidase inhibitors (XOIs) reduce the production of
uric acid (UA), its serum concentration, and UA crystal depo-
sition in joints, thereby reducing the risk of recurrent gout.
The production of UA by xanthine oxidase also generates free
radicals that might adversely affect mitochondrial function
and ATP production. XOIs might reduce free radical produc-
tion, leading to improved left ventricular (LV) function and
reverse LV remodeling and renal function.1–12 There is a sub-
stantial literature suggesting that serum UA concentrations
are associated with worse cardiovascular outcomes.13–15
However, UA is excreted by the kidney and therefore a
marker of renal function which is also strongly associated
with cardiovascular outcome. UA is also an anti-oxidant.16
Accordingly, there are theoretical reasons why XOI could
improve, worsen, or have no effect on cardiovascular
outcomes.17
We previously reported a systematic review of the effects
of XOI on mortality in randomized controlled trials (RCTs)
conducted in patients with cardiovascular disease.18 The
overall odds ratio (OR) and 95% conﬁdence intervals (CI)
were: 0.52 (0.19–1.40) suggesting that there might be a large
beneﬁt for XOIs, but with insufﬁcient evidence to be certain.
The recent EXACT-HF Study adds a substantial new dataset
using XOI for patients with heart failure (HF),19 and we were
also aware of a further recent study.20 We therefore up-
dated our systematic review.
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Methods
The study was designed according to the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
Statement.21 Inclusion criteria were as follows: RCTs com-
bined with XOI use. Participants were patients with known
cardiovascular disease. Observational studies and studies that
did not report mortality were excluded. There were no
language restrictions.
The PubMed/Medline, Embase, and Cochrane Central
Register of Controlled Trials database were searched until
September 2015. Studies were identiﬁed with the following
headings: allopurinol, oxypurinol, xanthine oxidase, cardio-
vascular disease, clinical trial, and randomized controlled
trial. We also searched reference lists of the retrieved articles
to identify other eligible studies.
Two investigators independently reviewed all titles, or titles
and abstracts from the search results to identify articles that
met the inclusion criteria. Selected trials were compared, and
disagreement was resolved by review team discussion and
consensus. If any of the eligibility criteria were not met, the
article was excluded. If results were incomplete or unclear,
attempts weremade to contact the study authors. Articles ﬁnally
selected for the review were checked to avoid inclusion of data
published in duplicate. Relevant information was collected on
baseline characteristics, NewYorkHeart Association (NYHA) func-
tional classiﬁcation, background cardiovascular disease, study
interventions, clinical outcomes at baseline, and end follow-up.
One study22 combined death and nonfatal myocardial infarc-
tion/stroke as a major adverse cardiac event and did not report
them separately. We included these events in the meta-analysis.
Of 183 articles identiﬁed by the initial search, 42 were retrieved
for more detailed evaluation. Only eight studies were included
in the review largely because of absence of mortality data.
Statistical analysis was carried out using the Review
Manager software (RevMan version 5.5). OR with 95% CI were
used to assess all-cause mortality between the two treatment
groups. Heterogeneity was assessed using chi-squared tests
as well as I-squared test. Forest plots are used to represent
the results generated from the random-effects meta-analysis
graphically. The pooled OR and the degree of heterogeneity
are presented. Publication bias was minimized by comprehen-
sive literature searching. In addition, a graphical display
(funnel plot) of the size of the treatment effect against the
precision of the trial (one/standard error) was used to investi-
gate publication bias. However, the funnel plot approach was
not used where the number of included studies was small.
Results
Eight studies were identiﬁed including 1031 patients (Table 1).
The average age of the patients was 61 ± 8 years, and 68%
were men excluding 113 patients in one study that did not re-
port gender. Where NYHA class was reported, most patients
were in class III or IV. Common adverse effects in the trials
are shown in Table 2.
Compared with placebo, initiation of XOI prior to coro-
nary artery bypass graft (CABG) surgery improved recovery
of cardiac function,23 maintained normal sinus rhythm after
open-heart surgery,24 and might have reduced heart muscle
injury and clinical outcomes after percutaneous coronary
intervention (PCI)25 in a series of small studies. One new
study20 showed that patients with high serum urate
assigned to allopurinol for three months after an acute
ischemic stroke had improved functional outcome evalu-
ated by a modiﬁed Rankin scale (OR = 4.65, p = 0.014).
However, there was no effect on mortality compared with
placebo (p = 0.28).
For patients with chronic HF, Gavin and Struthers26
showed that the plasma B-type natriuretic peptide (BNP) con-
centrations fell after 2–3months treatment with allopurinol
compared with placebo. However, Hare et al.27 reported that
there was no effect of XOI on NYHA class over 24weeks
(p = 0.42). The recent EXACT-HF study19 enrolled 253 pa-
tients with left ventricular ejection fraction (LVEF) ≤40%
and randomly allocated them to allopurinol or placebo.
There was no effect of allopurinol on the primary compos-
ite end point of survival, worsening HF, and patient global
assessment at 24weeks or LVEF despite a reduction in
serum acid.
The two new studies19,20 almost double the number of
deaths reported in trials of XOI in cardiovascular disease.
In the meta-analysis, there are now 1031 patients with
57 events. The mean duration of follow-up in the stud-
ies was about 5.4months. Although the OR for mortality
is 0.84 in favour of XOI, the 95% CI was wide
(0.48–1.47) (Figure 1). A funnel plot for publication bias
(Figure 2) suggests that it is unlikely that XOI have a strik-
ing effect on mortality but that substantial beneﬁt or
harm cannot be ruled out. Further analyses, conﬁned to
studies or subgroups with hyperuricaemia, provide a simi-
lar result.
Discussion
We found that use of XOI was associated with a reduction of
serum UA but there was no convincing evidence that this
translated into a reduction in mortality in patients with car-
diovascular disease.
Many studies have shown that elevated serum concen-
trations of UA are a risk factor for cardiovascular
events28,29 with the notable exception of Framingham
Heart Study that concluded that UA did not have a causal
role in the development of coronary heart disease and
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was not associated with either cardiovascular or all-cause
mortality.30 UA can have both pro- and anti-oxidant ef-
fects.31,32 Under normal conditions, reactive oxygen species
are generated by xanthine oxidase that may impair nitric
oxide production, and consequently induce endothelial dys-
function, and impair mitochondrial ATP production.33 UA
may also stimulate production of C-reactive protein, inhibit
endothelial cell proliferation, which can also cause endo-
thelial dysfunction,34 induce smooth muscle cell prolifera-
tion, and increase the production of angiotensin II.35
However, UA is excreted by the kidney. Renal impairment
will lead to both an increase in serum UA and is associated
with an increase in cardiovascular risk. Whether, serum UA
mediates some of the relationship between renal impair-
ment and cardiovascular risk is uncertain; serum UA may
just be an alternative to serum creatinine as a measure
of renal dysfunction.
Filipatos et al.36 showed an association between hyper-
uricaemia and all-cause mortality (HR with 95%CI: 1.4
(1.1–1.8), p = 0.005) and hospitalization for HF (HR with 95%
CI: 1.5 (1.2–1.9), p = 0.001) in patients with HF who did not
have chronic kidney disease (CKD), but this association did
not persist in those with CKD. They hypothesized that it
was over-production of UA with attendant oxidative stress
rather than simply an elevated plasma concentration of UA
that accounted for these observations. Ekundayo et al.37
showed similar associations amongst community dwelling
older adults.
Several observational studies suggest that allopurinol use
is associated with lower mortality but association does not
prove causality.38,39 Other treatments for gout have also
been purported to have effects on cardiovascular
outcome.40 A recent study41 suggested that colchicine use
was associated with a 73% reduction in all-cause mortality
over 16.5months in patients with gout. However, colchicine
users were more likely to take allopurinol (42% vs. 16%,
p< 0.0001). Allopurinol may just be a surrogate marker
for a different pattern or quality of care rather than an
effective treatment to reduce cardiovascular risk. Differ-
ences amongst studies might also reﬂect the dose of
allopurinol used.
There are several limitations to this analysis. Most RCTs
were single-centre which are more prone to investigator
biases, include few patients, and have a relatively short
follow-up time and very few events. Robust conclusions
should not be drawn from such data. The trials also studied
heterogeneous groups of patients who were at different risks
of mortality both in terms of rate and cause. The heterogene-
ity among the patients can explain the inconclusive results
and the wide conﬁdence limits of the analysis. The dose of
XOI might also be important. Doses of allopurinol ranged
from 100mg⁄day to 600mg⁄day. There might be a steep
dose–response relationship between allopurinol and its car-
diovascular effects.Ta
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In conclusion, studies of XOI conducted in patients with
cardiovascular disease do not suggest a large beneﬁt but also
do not exclude either substantial harm or beneﬁt. The opti-
mal dose of XOI is uncertain. Further large, multi-centre
randomized controlled clinical trials are required to ensure
the safety of using long-term XOI in patients with cardiovascu-
lar disease and hyperuricaemia and to conﬁrm that this leads
to a reduction in potential UA-related disease, such as gout
Table 2 Adverse effects reported with the use of allopurinol in chronic heart failure
Study Treatment Control
Treatment adverse effects
(% of patients)
Control adverse effects
(% of patients)
Coghlan 199423 Allopurinol
(300mg)
Each patient received
one tablet at 8 pm on
the evening before the
operation and one tablet
with their premedication
(1 h before the operation).
Placebo Two required
sodium nitroprusside
infusion to maintain
systolic blood pressure
below 120mm Hg
One required sodium
nitroprusside infusion
to maintain systolic
blood pressure below
120mm Hg
Gavin 200526 Allopurinol
(300mg/day)
Placebo Two patients developed
a skin rash
One patient developed
alopecia, one developed
severe back pain, one
developed diabetes
Hare 200827 Oxypurinol
(600mg/day)
Placebo — —
Talwar 201024 Allopurinol
(300mg the night
before the surgery)
Placebo The highest value of
troponin T=3.5 ng/mL;
After 24 h the highest
value of troponin
T=4.0 ng/mL
The highest value
of troponin T=3.2 ng/mL;
After 24 h the highest value
of troponin T=4.0 ng/mL
Rentoukas 200922 Allopurinol
(loading dose 400mg
followed by 100mg
for 1month)
Placebo — —
Goicoechea 201042 Allopurinol
(100mg/day)
Usual therapy No hematologic alterations
or serious adverse events
in relation to allopurinol
treatment appeared in the
follow-up study
—
Taheraghdam 201420 Allopurinol
(200mg/day)
Placebo Skin rashes or dermatitis
4 (11.4%)
Nausea 6 (17.1%)
Abdominal pain 4 (11.4%)
Diarrhea 4 (11.4%)
Hepatic enzyme
disorders 2 (5.7%)
Drowsiness 4 (11.4%)
Paresthesia 1 (2.8%)
Headache 7 (20%)
Skin rashes or dermatitis 0
Nausea 5 (14.2%)
Abdominal pain 2 (5.7%)
Diarrhea 3 (8.5%)
Hepatic enzyme
disorders 1 (2.8%)
Drowsiness 5 (14.2%)
Paresthesia 1 (2.8%)
Headache 9 (25.7%)
Figure 1 Forest plots of odds ratios for risk of mortality with the exception of the trial by Rentoukas (2009) that only reported a composite of death,
stroke, and myocardial infarction. Removing this trial did not materially alter the overall result [odds ratio and 95% conﬁdence interval: 0.92
(0.50–1.68)].
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and renal dysfunction. This will demonstrate whether or not
XOI reduce cardiovascular morbidity and mortality. Future
studies might stratify patients not only on serum UA concen-
tration but also renal function to tease out the respective
roles of high serum UA concentration and high UA production.
Conﬂict of interest
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Funding
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Figure 2 Funnel plot of estimates of the intervention effect from individ-
ual studies. Effect estimates from small studies are nearer the bottom of
the graph with larger studies nearer the top. There is evidence of publi-
cation bias with several small studies suggesting a large beneﬁt but no
small studies suggesting substantial harm. Larger studies (although they
are still small) in this meta-analysis are closer to neutrality. This may lead
to an overestimate of beneﬁt in this meta-analysis.43,44
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